After radical inguinal orchidectomy (orchiectomy), the histopathology report identifies the type of testicular germ cell tumour. This distinction matters because seminoma and non-seminomatous germ cell tumours (NSGCT) may require different decisions about surveillance, chemotherapy, radiotherapy and retroperitoneal lymph node dissection (RPLND).
Patients may search for phrases such as “seminoma vs non-seminoma,” “testicular cancer histopathology report,” “mixed germ cell tumour,” “AFP raised testicular cancer,” “Stage I seminoma treatment,” “non-seminoma treatment options,” or “RPLND for seminoma.”
Dr. Swati H. Shah is a uro- and gynaecologic oncosurgeon in Ahmedabad with a surgical interest in testicular cancer, RPLND and complex retroperitoneal disease. Treatment planning should be based on the full pathology report, tumour-marker trend, staging scans and discussion with the appropriate specialist team.
Seminoma is a type of testicular germ cell tumour. It commonly occurs in adults and is generally sensitive to radiotherapy and cisplatin-based chemotherapy. Many patients with Stage I seminoma are cured by orchidectomy alone and can be followed with active surveillance.
Histopathology reports may use terms such as:
The exact terminology depends on the specimen and the pathology reporting system. The report should be reviewed as a whole; one feature alone does not determine the entire treatment plan.
AFP (alpha-fetoprotein) should not be elevated because of a pure seminoma. If AFP is raised, the team must consider other explanations and review whether a non-seminomatous component is present or the original classification needs clarification.
Beta-hCG may be elevated in some seminomas, while LDH is a non-specific marker. Normal markers do not rule out seminoma, and elevated markers require interpretation in context.
Non-seminomatous germ cell tumour, often shortened to NSGCT or non-seminoma, includes several tumour types. A tumour may contain one component or a mixture of components.
Common terms in pathology reports include:
A mixed germ cell tumour may contain both seminomatous and non-seminomatous elements. When a non-seminomatous component is identified, treatment planning generally follows the non-seminoma pathway rather than treating the case as pure seminoma.
AFP may be elevated in some non-seminomatous tumours, particularly those with a yolk sac tumour component. Beta-hCG can be elevated in some non-seminomatous tumours, and LDH may contribute to the overall assessment.
Marker patterns are clues, not a substitute for histopathology. Not every non-seminomatous tumour raises all markers, and normal markers do not exclude disease.
Feature • Seminoma • Non-seminomatous germ cell tumour
— • — • —
Pathology • Seminoma without a non-seminomatous component • Includes embryonal carcinoma, yolk sac tumour, choriocarcinoma, teratoma or mixed components
AFP • Should not be elevated in pure seminoma • May be elevated, depending on components
Beta-hCG • May be elevated in some cases • May be elevated in some cases
Stage I management • Surveillance is a key option; selected patients may discuss adjuvant carboplatin • Surveillance, selected adjuvant chemotherapy or selected RPLND depending on risk and circumstances
Stage II management • Chemotherapy or radiotherapy are established options; RPLND is emerging for carefully selected low-volume Stage IIA/B disease • Treatment depends on marker status, nodal burden and clinical stage; RPLND has an established role in selected marker-negative Stage IIA disease
Residual mass after chemotherapy • Often assessed differently; FDG-PET may be used in selected seminoma residual masses of appropriate size and timing • Residual masses may contain teratoma or viable tumour and often require surgical assessment when indicated
Role of RPLND • A newer option for selected marker-negative Stage IIA/B seminoma in specialised centres; not routine for Stage I with no nodal disease • Used in selected clinical situations, including some Stage I and marker-negative Stage IIA cases and residual post-chemotherapy disease
This comparison is a general guide. Treatment decisions depend on the exact stage, markers, scans, pathology and patient circumstances.
Stage I seminoma generally means that the tumour has been removed and staging has not identified metastatic disease. The main post-orchidectomy options are:
Surveillance means planned follow-up with clinical review and scheduled imaging, with tumour markers when appropriate. It is a preferred option for many patients because most Stage I seminomas are cured by orchidectomy alone.
Surveillance does not mean no care. It requires reliable attendance at appointments and completion of the recommended tests.
Selected patients may discuss a single course of carboplatin after orchidectomy to reduce the risk of relapse. It can be considered according to the patient’s risk factors, preferences and ability to comply with surveillance.
Adjuvant chemotherapy exposes the patient to treatment that might not have been needed. The potential benefit and possible side effects should be discussed with the treating oncologist.
RPLND is not a routine standard treatment for clinical Stage I seminoma when there is no evidence of retroperitoneal lymph-node disease. For Stage I disease, surveillance is a key option, and selected patients may discuss adjuvant carboplatin.
RPLND is being studied and increasingly discussed for a different situation: clinical Stage IIA/IIB seminoma with limited retroperitoneal lymph-node disease. This is important to distinguish from Stage I disease with no visible nodal involvement.
Historically, seminoma with confirmed Stage II retroperitoneal lymph-node involvement has usually been treated with cisplatin-based chemotherapy or radiotherapy, depending on the stage and clinical circumstances. These treatments are effective but may have acute and long-term effects.
Recent prospective studies have evaluated primary retroperitoneal lymph node dissection (pRPLND) for carefully selected patients with low-volume, marker-negative Stage IIA/B seminoma. The aim is to remove the affected retroperitoneal nodes and potentially avoid or reduce exposure to chemotherapy or radiotherapy for some patients.
The 2026 European Association of Urology guidance recognises nerve-sparing RPLND as a primary treatment option for selected patients with marker-negative Stage IIA/B seminoma and low-volume lymph-node disease, when performed by experienced surgeons in specialised, high-volume centres. Evidence is promising, but recurrence can occur and longer-term comparative data remain important.
Selection is specialist-led and depends on factors such as:
The size and number of nodes, their location, imaging certainty and other clinical features all matter. Not every patient with an enlarged node is a suitable candidate.
For carefully selected patients, potential advantages may include:
These are potential advantages, not guarantees. Some patients relapse after RPLND and may need chemotherapy or further treatment.
RPLND is a major operation involving lymph nodes near the aorta, inferior vena cava, renal vessels, ureters and autonomic nerves. Potential complications include bleeding, infection, lymphatic leak or chylous ascites, injury to nearby structures, and changes in ejaculation.
The extent of dissection and whether a nerve-sparing approach is possible depend on the disease distribution and surgical findings. RPLND should not be presented as universally safer or better than chemotherapy or radiotherapy. The options should be compared in a specialist consultation.
Robotic RPLND may be considered in selected cases when the disease pattern, node size, anatomy and surgical objectives are appropriate and the team has relevant experience. Open surgery may be preferable in other situations. The choice of surgical approach is separate from the decision about whether RPLND itself is appropriate.
Patients should ask about the surgeon’s experience, the planned dissection template, recurrence monitoring, nerve-sparing possibilities and the plan if final pathology or follow-up indicates further treatment.
Reports may use terms such as:
Stage II means that cancer has spread to regional lymph nodes. The size, number and distribution of nodes, marker status and other staging findings help determine the exact category and treatment.
Small or borderline nodes do not always represent definite metastasis. When imaging is equivocal and markers are normal, the team may recommend repeat imaging or further assessment before committing to treatment.
For confirmed Stage IIA/B seminoma, the discussion may include chemotherapy, radiotherapy and—where criteria and expertise are appropriate—primary RPLND. This is a different clinical decision from routine Stage I seminoma management.
For Stage I NSGCT, management after orchidectomy may include surveillance, adjuvant chemotherapy or RPLND in selected circumstances. Lymphovascular invasion (LVI) is an important factor in recurrence-risk assessment.
For selected patients with marker-negative Stage IIA NSGCT, RPLND may be a treatment option. If tumour markers are elevated or rising, systemic treatment is often considered according to the clinical stage and prognostic classification.
After chemotherapy, a residual retroperitoneal mass in NSGCT can contain mature teratoma or viable cancer, even when tumour markers have normalised. Surgery may therefore be recommended for selected residual masses. This differs from seminoma, where residual-mass evaluation follows a different pathway.
AFP is not expected to be elevated in a pure seminoma. If the pathology report says seminoma but AFP remains elevated, the team should review the result, its trend, possible non-cancer causes and the pathology classification. An expert pathology review may be appropriate if the result could change treatment.
Do not assume that one test automatically overrides all the others. The discrepancy needs a structured clinical review.
Treatment planning should include questions about fertility and sexual function. Before chemotherapy or major retroperitoneal surgery, patients who may want biological children should discuss sperm banking when feasible.
RPLND can affect ejaculation because of the location of the sympathetic nerves. Nerve-sparing techniques may preserve antegrade ejaculation in selected cases, but this cannot be guaranteed. Ask the team about the planned surgical template, nerve-sparing intent and potential need for additional treatment.
Long-term care should also consider hormone symptoms, emotional wellbeing, cardiovascular and other health risks after treatment, and follow-up for recurrence or late effects.
They are different types of testicular germ cell tumour. Histopathology establishes the tumour type and helps determine which treatment pathways are appropriate.
RPLND is not routine for Stage I seminoma when staging shows no retroperitoneal lymph-node disease. Surveillance is a key option after orchidectomy, and selected patients may discuss adjuvant carboplatin.
Yes, for carefully selected patients with marker-negative clinical Stage IIA/B seminoma and low-volume retroperitoneal lymph-node disease, RPLND is an emerging option recognised in contemporary European guidance when performed in specialised, high-volume centres. It is not suitable for every patient, and further long-term evidence is important.
No. Chemotherapy and radiotherapy remain established treatments for Stage II seminoma. RPLND is an option for selected patients after specialist assessment and discussion of the benefits, risks and uncertainty.
AFP should not be elevated in pure seminoma. If it is raised, the clinical team should evaluate possible alternative causes and review the diagnosis if necessary.
LVI means tumour cells are seen within lymphatic or blood vessels in the specimen. It is an important recurrence-risk factor in Stage I non-seminomatous germ cell tumour and may affect the treatment discussion.
It may be suitable in selected cases, depending on the tumour’s size, location, previous treatment and the surgical team’s experience. Robotic surgery is not automatically the best approach for every patient.
Bring the orchidectomy histopathology report, AFP/beta-hCG/LDH results with dates, CT reports and images, operative notes and details of any chemotherapy or radiotherapy.
| Tumour type | Risk factors | Usual options |
|---|---|---|
| Seminoma | Size above 4 cm, rete testis invasion | Surveillance, or one dose of carboplatin |
| Non-seminoma, low risk | No lymphovascular invasion | Surveillance |
| Non-seminoma, high risk | Lymphovascular invasion | One to two cycles of BEP, or selected nerve-sparing RPLND |
Seminoma is a uniform germ-cell tumour that is highly sensitive to radiotherapy and chemotherapy and usually grows more slowly. Non-seminomatous tumours (embryonal carcinoma, yolk sac, choriocarcinoma, teratoma, mixed) grow faster, often raise AFP or hCG, and are managed differently.
No. A raised AFP means non-seminomatous elements are present, so the tumour is treated as a non-seminoma even when the report says pure seminoma.
In Stage I seminoma, tumour size above 4 cm and rete testis invasion are the usual risk factors. In Stage I non-seminoma, lymphovascular invasion is the main one. They guide the choice between surveillance and adjuvant treatment.
Selected videos and anonymised case summaries from Dr Swati Shah’s testicular cancer practice, shared for patient education. Every patient’s plan is individual, and a past case does not predict an individual result.
When a testicular tumour is suspected, the surgical approach is extremely important. A scrotal incision should generally be avoided because it can disrupt the normal lymphatic drainage pathways of the testis and potentially increase the risk of local tumour contamination and altered patterns of spread.
The standard oncological procedure for a suspected testicular malignancy is high inguinal orchidectomy. Through an inguinal approach, the testis is delivered and removed along with the spermatic cord and its vascular and lymphatic pedicle, providing appropriate oncological control and allowing accurate histopathological diagnosis.
This is an important surgical principle: the first incision matters. An incorrect approach can complicate subsequent management, while the appropriate initial procedure can help ensure proper staging and treatment.
जब टेस्टिकुलर ट्यूमर (Testicular Tumour) का संदेह हो, तो सर्जरी का सही तरीका बहुत महत्वपूर्ण होता है। आमतौर पर अंडकोष (Scrotum) पर चीरा लगाने से बचना चाहिए, क्योंकि इससे अंडकोष की सामान्य लिम्फेटिक ड्रेनेज (Lymphatic drainage) प्रभावित हो सकती है और स्थानीय रूप से ट्यूमर कोशिकाओं के फैलने तथा बीमारी के फैलाव के तरीके में बदलाव का जोखिम बढ़ सकता है।
संदिग्ध टेस्टिकुलर कैंसर में मानक ऑन्कोलॉजिकल सर्जरी हाई इंग्वाइनल ऑर्किडेक्टॉमी (High Inguinal Orchidectomy) है। इसमें जांघ के ऊपरी हिस्से के पास इंग्वाइनल (Inguinal) रास्ते से अंडकोष को बाहर निकालकर, उसे स्पर्मेटिक कॉर्ड (Spermatic cord) तथा उसकी रक्त वाहिकाओं और लिम्फेटिक पेडिकल (Lymphatic pedicle) सहित हटाया जाता है। इससे उचित कैंसर सर्जरी सुनिश्चित होती है और सही हिस्टोपैथोलॉजिकल डायग्नोसिस (Histopathological diagnosis) में मदद मिलती है।
यह एक महत्वपूर्ण सर्जिकल सिद्धांत है: पहला चीरा बहुत मायने रखता है। गलत तरीके से किया गया पहला ऑपरेशन आगे के उपचार को जटिल बना सकता है, जबकि सही शुरुआती सर्जिकल प्रक्रिया बीमारी की उचित स्टेजिंग और आगे के उपचार में मदद करती है।
Advanced testicular cancer can still be curable, even when large residual lymph node masses remain after chemotherapy.
In this case, a 30-year-old man with a mixed germ cell tumor of the testis received systemic chemotherapy and subsequently underwent evaluation for a residual retroperitoneal lymph node mass. PET-CT showed significant residual masses measuring approximately 6 × 5 cm and 5 × 5 cm, located close to major blood vessels, including the aorta, inferior vena cava (IVC), and renal vessels.
Because of the size and location of the residual disease, surgery was technically challenging. The patient underwent exploratory laparotomy with retroperitoneal lymph node dissection (RPLND). Despite the close relationship of the tumor to the major vessels, a complete surgical resection was achieved safely, with removal of all visible residual tumor tissue.
In the video, He speaks in Gujarati, sharing his personal experience. He explains that he initially visited the clinic because he was experiencing significant pain. After a thorough medical evaluation, he was diagnosed with cancer and advised to undergo surgical intervention. Guided by the medical expertise of Dr. Swati Shah, He confidently went ahead with the recommended operation. The surgery was a success, and he reports receiving a highly positive response to the procedure. Following the operation, his comprehensive treatment plan also included a round of chemotherapy to reduce the risk of relapse.
This video presents a compelling testimonial from a testicular cancer survivor who received life-saving treatment from Dr. Swati Shah, an expert Uro and Gynecological Oncologist. In the brief clip, the patient recounts their challenging medical journey, focusing on the critical decision-making process regarding their surgical treatment plan. Initially confronted with the difficult prospect of traditional open surgery—which typically involves a longer, more painful healing process—the patient instead opted for a state-of-the-art robotic surgery performed by Dr. Shah. The survivor shares how this advanced, minimally invasive approach made a massive difference in their overall recovery.
The patient explains that he was initially diagnosed with testicular cancer five years ago. Unfortunately, eight months prior to the video, he faced a recurrence involving a retroperitoneal lymph node. After finding Dr. Swati Shah online, he underwent a complex robotic Retroperitoneal Lymph Node Dissection (RPLND) surgery performed by her. Speaking just two months post-operation, the patient highlights his remarkably smooth and rapid recovery, noting that his follow-up medical reports have all been positive. He expresses deep gratitude and recommends Dr. Shah.
“Dr. Swati Shah operated successfully and provided excellent care throughout the treatment. She is highly skilled, compassionate, and undoubtedly the best doctor for testis cancer in Ahmedabad. We are very thankful for her guidance and expertise”
Raval Prakash · Patient, Google review
“We had surgery done in Apollo Hospital. The doctor is very good and has done the options in a very good way. Now everything is fine.”
Hiren Solanki · Patient, Google review
“Her guidance, expertise, and caring attitude make the treatment journey much easier for patients and their families. She explains everything clearly and ensures the patient feels comfortable and confident throughout the process.”
Rakshit Ramani · Patient, Google review
A 36-year-old man had a hard, non-tender right testicular swelling for one year. Imaging showed a complex 7.3 × 6.3 cm lesion with raised LDH and AFP. Because of its size and possible involvement of the scrotal wall, a right high inguinal orchidectomy was performed.
A 19-year-old man presented with rapid testicular swelling and abdominal discomfort for about two weeks. A 3.5 cm testicular lesion and a markedly raised AFP (above 1000) pointed to a high-risk non-seminomatous germ cell tumour (NSGCT), and prompt high inguinal orchidectomy was planned.
Details are anonymised and shown for education only.
Dr. Swati H. Shah is a uro- and gynaecologic oncosurgeon in Ahmedabad with a surgical interest in testicular cancer, RPLND and complex retroperitoneal disease.
If your histopathology report says seminoma, non-seminomatous germ cell tumour or mixed germ cell tumour—or if you have been told that RPLND may be an option—bring your pathology, tumour markers and staging images for review. The appropriate plan depends on the exact tumour type, stage, marker status and clinical circumstances.
Consultation: Shah’s Cancer & Robotic Surgery Centre, Gota, Ahmedabad.
Hospital: Apollo Hospital International, Ahmedabad, as appropriate.
Contact: +91 63590 11009
This page is for general education and does not replace an individual medical consultation. Treatment decisions should be made with an experienced multidisciplinary team using current guidelines and the patient’s complete clinical information.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
